FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, pharmaceutics and biochemistry, and concerns a metastatic melanoma grade marker containing the amino acid sequence SEQ ID NO:1. There are also declared a recovered antibody and a monoclonal antibody, which recognise human TM9SF4 protein by binding to a peptide fragment of SEQ ID NO:1, as well as a kit for determining a tumour grade comprising the above antibody, using SEQ ID NO:1 for determining the metastatic pattern of melanoma.
EFFECT: group of inventions provides the faster detection of melanoma metastasis.
10 cl, 8 ex, 2 tbl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| TOM34 GENE RELATED TO COLON CANCER | 2006 |
|
RU2526196C2 |
| COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
| GENE TOM34 ASSOCIATED WITH CANCER OF LARGE INTESTINE | 2006 |
|
RU2449020C2 |
| NOVEL TUMOUR BIOMARKER | 2010 |
|
RU2567005C2 |
| CDC45L PEPTIDES AND VACCINES CONTAINING SAME | 2010 |
|
RU2562160C2 |
| HOMODIMER PROTEIN CONSTRUCTION | 2011 |
|
RU2624041C2 |
| MTS GENE, MUTATIONS OF THIS GENE AND METHODS OF DIAGNOSIS OF MALIGNANT TUMORS USING MTS GENE SEQUENCE | 1995 |
|
RU2164419C2 |
| RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF | 2015 |
|
RU2682335C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
